iPSC-derived cells for whole liver bioengineering

Front Bioeng Biotechnol. 2024 Feb 7:12:1338762. doi: 10.3389/fbioe.2024.1338762. eCollection 2024.

Abstract

Liver bioengineering stands as a prominent alternative to conventional hepatic transplantation. Through liver decellularization and/or bioprinting, researchers can generate acellular scaffolds to overcome immune rejection, genetic manipulation, and ethical concerns that often accompany traditional transplantation methods, in vivo regeneration, and xenotransplantation. Hepatic cell lines derived from induced pluripotent stem cells (iPSCs) can repopulate decellularized and bioprinted scaffolds, producing an increasingly functional organ potentially suitable for autologous use. In this mini-review, we overview recent advancements in vitro hepatocyte differentiation protocols, shedding light on their pivotal role in liver recellularization and bioprinting, thereby offering a novel source for hepatic transplantation. Finally, we identify future directions for liver bioengineering research that may allow the implementation of these systems for diverse applications, including drug screening and liver disease modeling.

Keywords: bioengineering; bioprinting; decellularization; human induced pluripotent stem cells; liver.

Publication types

  • Review

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors sincerely acknowledge the support of the Sao Paulo Research Foundation (FAPESP/CEPID and CCD) (2013/08028-1 and 2021/11872-5, respectively). KT-S is a FAPESP grantee (2019/19380-4 and 2022/08157-5). LP, FC, and SK are CAPES grantees (88887.816556/2023-00, 88882.461730/2019-01, and 88887.816557/2023-00, respectively).